MedTrace Logo

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

NCT01330758 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-07-29

No results posted yet for this study

Summary

A study to compare two different tablet formulations of AZD8931 in healthy males and females.

Conditions

  • Healthy

Interventions

DRUG

AZD8931

40 mg AZD8931 wet granulation tablet formulation

DRUG

AZD8931

40 mg AZD8931 roller compacted tablet formulation

Sponsors & Collaborators

Principal Investigators

  • Mary Stuart · AstraZeneca,1F64, Mereside, Alderley Park, Macclesfield, Cheshire,SK10 4TG UK

  • Dr Darren Wilbraham, DICP, MBBS · Quintiles Drug Research Unit at Guy's Hospital

  • Jason Clark, BSc · Quintiles Drug Research Unit at Guy's Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330758 on ClinicalTrials.gov